THE MODERN BIOHEALTH, WITH PERSPECTIVE.
Clinician-led care in Florida

WEIGHT & METABOLIC HEALTH / PRACTITIONER-GUIDED

Other weight-management medications

EvidenceEvidence in context
FDA-approved products have human efficacy data for defined chronic weight-management indications; benefits and risks differ substantially by drug.
RegulatoryProduct-specific
Prescription or OTC depending on product; indication and formulation specific
Corrections & editorial standards
GLP-1 drugs are not the only evidence-based option: phentermine/topiramate, naltrexone/bupropion and orlistat may fit selected patients after individualized screening.Create account & prepare for review Practitioner review required · A prescription is never guaranteed.
Body composition assessment representing non-GLP-1 weight-management options
Metabolic treatment guide
WHAT IT MAY HELP WITH

Provides non-GLP-1 pathways for chronic weight management when eligibility, contraindications, side effects, cost and long-term adherence are considered together.

EVIDENCE

FDA-approved products have human efficacy data for defined chronic weight-management indications; benefits and risks differ substantially by drug.

STATUS

Prescription or OTC depending on product; indication and formulation specific

WHO MAY BE CONSIDERED

Eligibility starts with your complete health context.

  • ✓A chronic weight-management indication is established
  • ✓A GLP-1 medicine is not preferred, tolerated or accessible
  • ✓Blood pressure, pregnancy potential, mental health, seizure and medication history can be reviewed

WHAT A PRACTITIONER REVIEWS

The information that shapes the decision.

  • Weight history, BMI and weight-related conditions
  • Blood pressure, heart rate, mood, seizure and glaucoma history
  • Pregnancy plans, current medicines and prior treatment response

IMPORTANT SAFETY INFORMATION

Reasons treatment may not be appropriate.

  • !Phentermine-containing products can raise heart rate and blood pressure and have controlled-substance considerations.
  • !Naltrexone/bupropion is incompatible with opioid use and has seizure, blood-pressure and psychiatric warnings.
  • !Orlistat causes GI effects and can affect absorption of fat-soluble vitamins and some medicines.

ORIGINAL SOURCES

Review the evidence behind the option.

FDA Drugs@FDA: chronic weight-management productsFDA review: naltrexone/bupropion for obesity

OTHER PRESCRIPTION OPTIONS

MetabolicGLP-1–based medicationsView details →HormonesTestosterone therapyView details →HormonesMenopause hormone therapyView details →

YOUR NEXT STEP

Ready for a clinician-led plan?

Clinical review determines the appropriate next step. No treatment is guaranteed.

THE CARE PATH

  1. We order your labs

  2. A licensed clinician reviews results and recommends a plan

  3. Rx sent directly to you when appropriate

Care depends on eligibility and clinical judgment. No prescription is guaranteed. This pathway is not a recommendation for the treatment or test discussed in this guide.

Start your lab reviewExplore free educational tools